The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2-Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230)
Abstract
Aromatase inhibitors reduce estrogen levels in postmenopausal women with breast cancer. Residual estrogen is an important determinant of bone turnover. Adjuvant anastrozole was associated with significant BMD loss and increased bone remodeling, whereas tamoxifen reduced bone marker levels. Introduction: In the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial after a median follow-up of 68 months, a significant improvement in disease-free survival was observed with anastrozole treatment (hazard ratio [HR], 0.87; 95% CI, 0.78–0.97; p = 0.01). Anastrozole was also associated with tolerability benefits compared with tamoxifen, but with higher fracture rates. The HR of anastrozole compared with tamoxifen after 60 months of treatment was 1.49 (95% CI, 1.25–1.77). Materials and Methods: This prospectively designed subprotocol (n = 308) of ATAC assessed changes in BMD and bone turnover markers in postmenopausal women with invasive primary breast cancer receiving anastrozole 1 mg/day, tamoxifen 20 mg/day, or combination treatment with both agents for 5 years. Patients with osteoporosis were excluded (osteopenia permitted at the investigators discretion). Lumbar spine and total hip BMD was assessed at baseline and after 1 and 2 years; bone turnover markers (serum C-telopeptide, urinary N-telopeptide [NTX], free deoxypyridinoline, serum procollagen type-1 N-propeptide, bone alkaline phosphatase [ALP]) were assessed at baseline and after 3, 6, and 12 months. Results were expressed as median percentage change. Results: After 2 years of anastrozole treatment, BMD was lost at lumbar spine (median 4.1% loss) and total hip (median 3.9% loss) sites; increases of 2.2% and 1.2%, respectively, were observed with tamoxifen. After 1 year of anastrozole treatment, increased bone remodeling was observed (NTX, +15%; 95% CI, 3–25%; bone ALP, +20%; 95% CI, 14–25%); decreased bone remodeling was observed with tamoxifen (NTX, −52%; 95% CI, −62% to −33%; bone ALP, −16%; 95% CI, −24% to −11%). Conclusions: Anastrozole is associated with significant BMD loss and a small increase in bone turnover, whereas tamoxifen (and the combination) is associated with increased BMD and decreased remodeling. These data may explain the increased fracture risk observed with anastrozole treatment in the ATAC trial. The impact of anastrozole on bone should be weighed against its overall superior efficacy and tolerability as observed in the main ATAC trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261302 · Cited by 1,129
The Nottingham prognostic index in primary breast cancer
Galea, M. H., Blamey, R. W., Elston, C. E., & Ellis, I. O. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01840834 · Cited by 1,070
Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 970
The ATAC (Arimidex, T. A. O. I. C. T. G. (2003) · Cancer · doi:10.1002/cncr.11745 · Cited by 861
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09962-2 · Cited by 747
Garnero, P., Sornay-Rendu, E., Claustrat, B., & Delmas, P. D. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1526 · Cited by 709
Endogenous Hormones and the Risk of Hip and Vertebral Fractures among Older Women
Cummings, S. R., Browner, W. S., Bauer, D., Stone, K., Ensrud, K., Jamal, S., & Ettinger, B. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391104 · Cited by 660
Powles, T. J., Hickish, T., Kanis, J. A., Tidy, A., & Ashley, S. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.78 · Cited by 646
Characterization of Perimenopausal Bone Loss: A Prospective Study
Recker, R., Lappe, J., Davies, K., & Heaney, R. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.10.1965 · Cited by 335
Lønning, P. E., Geisler, J., Krag, L. E., Erikstein, B., Bremnes, Y., Hagen, A. I., Schlichting, E., Lien, E. A., Øfjord, E. S., Paolini, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.097 · Cited by 295 · cited 1×
“Studies on mechanism have indicated that letrozole and exemestane are also associated with higher levels of bone resorption markers((11,33,34)) and faster rates of bone loss((34))”
BackgroundEttinger, B., Pressman, A., Sklarin, P., Bauer, D. C., Cauley, J. A., & Cummings, S. R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4708 · Cited by 258
Dowsett, M., Goss, P. E., Powles, T., Hutchinson, G., Brodie, A. M., Jeffcoate, S. L., & Coombes, R. C. (1987) · PubMed · Cited by 238
Self-citationHeshmati, H. M., Khosla, S., Robins, S. P., O'Fallon, W. M., Melton, L. J., & Riggs, B. L. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.1.172 · Cited by 207
Rogers, A., Saleh, G., Hannon, R. A., Greenfield, D., & Eastell, R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020396 · Cited by 200
Self-citationDeterminants of Bone Loss in Elderly Men and Women: A Prospective Population-Based Study
Dennison, E., Eastell, R., Fall, C. H. D., Kellingray, S., Wood, P. J., & Cooper, C. (1999) · Osteoporosis International · doi:10.1007/s001980050244 · Cited by 183
Self-citationEttinger, B. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.7.2239 · Cited by 180
The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women
Grey, A. B., Stapleton, J. P., Evans, M. C., Tatnell, M. A., Ames, R. W., & Reid, I. R. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80251-4 · Cited by 154
Harper-Wynne, C. L., Ross, G., Sacks, N. P. M., Salter, J., Nasiri, N., Iqbal, J., A’Hern, R., & Dowsett, M. (2002) · PubMed · Cited by 147
Self-citationWard, R. L., Morgan, G., Dalley, D. N., & Kelly, P. J. (1993) · Bone and Mineral · doi:10.1016/s0169-6009(08)80220-6 · Cited by 130
Marttunen, M. B., Hietanen, P. S., Tiitinen, A. E., & Ylikorkala, O. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.4.4688 · Cited by 127
Chapurlat, R. D., Garnero, P., Bréart, G., Meunier, P. J., & Delmas, P. D. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.9.1835 · Cited by 98
‘Pure’ invasive apocrine carcinoma of the breast: a new clinicopathological entity?
Japaze, H., Emina, J., Diaz, C., Schwam, R. J., Gercovich, N., Demonty, G., Morgenfeld, E. L., Rivarola, E. G. J., Deza, E. G., & Gercovich, F. G. (2004) · The Breast · doi:10.1016/j.breast.2004.06.003 · Cited by 97
Wiseman, L. R., & Adkins, J. C. (1998) · Drugs & Aging · doi:10.2165/00002512-199813040-00008 · Cited by 58
Evidence that Tamoxifen Preserves Bone Density in Late Postmenopausal Women with Breast Cancer
Resch, A., Biber, E., Seifert, M., & Resch, H. (1998) · Acta Oncologica · doi:10.1080/028418698430007 · Cited by 53
Marttunen, M. B., Hietanen, P. S., Titinen, A., Roth, H. J., Viinikka, L. U., & Ylikorkala, O. (1999) · Calcified Tissue International · doi:10.1007/s002239900714 · Cited by 37
Chapurlat, R. D., Bauer, D. C., & Cummings, S. R. (2001) · Bone · doi:10.1016/s8756-3282(01)00584-1 · Cited by 32
Ragaz, J. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00159-5 · Cited by 9
Cited by
Use of bone turnover markers in postmenopausal osteoporosis
Eastell, R., & Szulc, P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30184-5 · Cited by 594
Self-citationAapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
Coleman, R. E., Banks, L. M., Girgis, S. I., Kilburn, L. S., Vrdoljak, E., Fox, J., Cawthorn, S. J., Patel, A., Snowdon, C. F., Hall, E., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70003-7 · Cited by 426
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Eastell, R., Adams, J. E., Coleman, R. E., Howell, A., Hannon, R. A., Cuzick, J., Mackey, J. R., Beckmann, M. W., & Clack, G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0726 · Cited by 407
Self-citation
Metadata
- Authors
- Eastell, R., Hannon, R. A., Cuzick, J., Dowsett, M., Clack, G., & Adams, J. E.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-08-01
- Volume
- 21
- Issue
- 8
- Pages
- 1215-1223
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1976680910
- Cited by
- 325
- References
- 32
- FWCI
- 34.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.